<span id="midArticle_start"/> (Reuters) - Dublin-based Perrigo Company Plc said its board unanimously rejected a $205 per shareoffer from generic drugmaker Mylan NV, saying the bidsubstantially undervalued the company.
<span id="midArticle_0"/>Perrigo said Mylan's offer did not take into accountPerrigo's 2.48 billion euros ($2.66 billion) acquisition ofOmega Pharma and new products that are expected to generateabout $1 billion in revenue.
<span id="midArticle_1"/>Earlier in the day, Reuters reported that Perrigo was set toreject the $29 billion offer from Mylan, as it tackles anunsolicited offer from Israeli drugmaker Teva PharmaceuticalIndustries Ltd. ($1 = 0.9316 euros) (Reporting by Vidya L Nathan in Bengaluru; Editing by SayantaniGhosh)
<span id="midArticle_2"/>
<span id="midArticle_0"/>Perrigo said Mylan's offer did not take into accountPerrigo's 2.48 billion euros ($2.66 billion) acquisition ofOmega Pharma and new products that are expected to generateabout $1 billion in revenue.
<span id="midArticle_1"/>Earlier in the day, Reuters reported that Perrigo was set toreject the $29 billion offer from Mylan, as it tackles anunsolicited offer from Israeli drugmaker Teva PharmaceuticalIndustries Ltd. ($1 = 0.9316 euros) (Reporting by Vidya L Nathan in Bengaluru; Editing by SayantaniGhosh)
<span id="midArticle_2"/>
via Smart Health Shop Forum http://ift.tt/1IEzv82
No comments:
Post a Comment